Loading...
Immunotherapy for head and neck cancer: Recent advances and future directions
Three randomized phase III trials have now conclusively proven that exposure to a PD-1 inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such agents should be used in the management of all patients who do not have contraindications to their use. Two of these phase...
Saved in:
| Published in: | Oral Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7749717/ https://ncbi.nlm.nih.gov/pubmed/31683169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.104460 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|